Royalty Pharma Statistics

Total Valuation

Royalty Pharma has a market cap or net worth of $32.38 billion. The enterprise value is $40.75 billion.

Market Cap	32.38B
Enterprise Value	40.75B

Important Dates

The next estimated earnings date is Wednesday, August 5, 2026, before market open.

Earnings Date	Aug 5, 2026
Ex-Dividend Date	May 15, 2026

Share Statistics

Royalty Pharma has 575.83 million shares outstanding. The number of shares has decreased by -5.11% in one year.

Current Share Class	443.27M
Shares Outstanding	575.83M
Shares Change (YoY)	-5.11%
Shares Change (QoQ)	+0.15%
Owned by Insiders (%)	6.22%
Owned by Institutions (%)	83.23%
Float	413.20M

Valuation Ratios

The trailing PE ratio is 29.53 and the forward PE ratio is 10.77. Royalty Pharma's PEG ratio is 1.00.

PE Ratio	29.53
Forward PE	10.77
PS Ratio	13.27
Forward PS	9.11
PB Ratio	3.62
P/TBV Ratio	5.43
P/FCF Ratio	n/a
P/OCF Ratio	12.40
PEG Ratio	1.00

Financial Ratio History

Enterprise Valuation

EV / Earnings	49.31
EV / Sales	16.70
EV / EBITDA	n/a
EV / EBIT	24.58
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.66, with a Debt / Equity ratio of 0.90.

Current Ratio	2.66
Quick Ratio	2.64
Debt / Equity	0.90
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	4.93

Financial Efficiency

Return on equity (ROE) is 13.77% and return on invested capital (ROIC) is 5.71%.

Return on Equity (ROE)	13.77%
Return on Assets (ROA)	5.54%
Return on Invested Capital (ROIC)	5.71%
Return on Capital Employed (ROCE)	8.60%
Weighted Average Cost of Capital (WACC)	5.78%
Revenue Per Employee	$24.41M
Profits Per Employee	$8.26M
Employee Count	100
Asset Turnover	0.13
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +56.59% in the last 52 weeks. The beta is 0.42, so Royalty Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.42
52-Week Price Change	+56.59%
50-Day Moving Average	52.65
200-Day Moving Average	43.81
Relative Strength Index (RSI)	61.03
Average Volume (20 Days)	4,712,878

Short Selling Information

The latest short interest is 11.59 million, so 2.01% of the outstanding shares have been sold short.

Short Interest	11.59M
Short Previous Month	12.68M
Short % of Shares Out	2.01%
Short % of Float	2.80%
Short Ratio (days to cover)	2.76

Income Statement

In the last 12 months, Royalty Pharma had revenue of $2.44 billion and earned $826.29 million in profits. Earnings per share was $1.90.

Revenue	2.44B
Gross Profit	2.81B
Operating Income	1.66B
Pretax Income	1.36B
Net Income	826.29M
EBITDA	n/a
EBIT	1.66B
Earnings Per Share (EPS)	$1.90

Full Income Statement

Balance Sheet

The company has $608.30 million in cash and $8.97 billion in debt, giving a net cash position of -$8.37 billion or -$14.53 per share.

Cash & Cash Equivalents	608.30M
Total Debt	8.97B
Net Cash	-8.37B
Net Cash Per Share	-$14.53
Equity (Book Value)	9.94B
Book Value Per Share	15.53
Working Capital	890.13M

Full Balance Sheet

Cash Flow

Operating Cash Flow	2.61B
Capital Expenditures	n/a
Depreciation & Amortization	5.02M
Net Borrowing	954.48M
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 115.00%, with operating and profit margins of 67.93% and 33.86%.

Gross Margin	115.00%
Operating Margin	67.93%
Pretax Margin	55.64%
Profit Margin	33.86%
EBITDA Margin	n/a
EBIT Margin	67.93%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of $0.94, which amounts to a dividend yield of 1.67%.

Dividend Per Share	$0.94
Dividend Yield	1.67%
Dividend Growth (YoY)	5.81%
Years of Dividend Growth	5
Payout Ratio	47.79%
Buyback Yield	5.11%
Shareholder Yield	6.83%
Earnings Yield	2.55%
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for Royalty Pharma is $59.25, which is 5.37% higher than the current price. The consensus rating is "Buy".

Price Target	$59.25
Price Target Difference	5.37%
Analyst Consensus	Buy
Analyst Count	10
Revenue Growth Forecast (3Y)	18.45%
EPS Growth Forecast (3Y)	9.16%

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Royalty Pharma has an Altman Z-Score of 1.61 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.61
Piotroski F-Score	6